The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
about
Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide.Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein.Synergizing vaccinations with therapeutics for measles eradicationHuman immunodeficiency virus reverse transcriptase and protease sequence databaseEmergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.Measles virus entry inhibitors: a structural proposal for mechanism of action and the development of resistance.Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide StrategyEnfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection.N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.Peptide aptamers: recent developments for cancer therapy.Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicidesHydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeuticA human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitopeThe prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions.HIV-1 antiretroviral resistance: scientific principles and clinical applicationsPharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system.Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kineticsEnfuvirtide.Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histoculturesPeptides corresponding to the predicted heptad repeat 2 domain of the feline coronavirus spike protein are potent inhibitors of viral infectionOrally active fusion inhibitor of respiratory syncytial virusEnfuvirtide: antiretroviral class 4, drug 1.Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice.Nanotechnology and the treatment of HIV infection.The entry of entry inhibitors: a fusion of science and medicine.A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.Enfuvirtide: the first HIV fusion inhibitor.Developments towards effective treatments for Nipah and Hendra virus infection.Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-1.Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactionsA cholesterol tag at the N terminus of the relatively broad-spectrum fusion inhibitory peptide targets an earlier stage of fusion glycoprotein activation and increases the peptide's antiviral potency in vivo.Targeted strategies for henipavirus therapeuticsMeasles control--can measles virus inhibitors make a difference?Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.Enfuvirtide: from basic investigations to current clinical use.Mechanism of HIV antiretroviral drugs progress toward drug resistance.Extolling the benefits of molecular therapeutic lipidation.
P2860
Q24535758-B9CEEF16-1E6F-453D-A6F9-4BCCE2249DDCQ24814238-0D9A18F5-1EF9-49E9-B765-73CC728C072CQ27003149-057D9F3B-5039-41BC-92D7-556239F2C848Q29616403-3E8759BD-4CA7-496B-93C6-E4589778A8FDQ29619254-15D5CBBB-B74F-40CC-8EC7-D0004827D8DBQ30583105-C191E182-34D2-4B95-B7D1-215356041C49Q30661709-FDF6E41D-9C60-42BF-9D71-2568C8452260Q30758170-60D53383-6D4D-4EF3-B30F-48DB6ACF9148Q33208281-4B956AD4-9F37-4639-AA9D-35A6BEEC4B80Q33216999-7C4605DA-5617-4DA7-A098-93CC0A2858D7Q33559031-AED1B9B0-DC45-4946-A2F5-A4185464E0F5Q33984351-04E097BD-819A-4ABD-87CC-C3536A0971C4Q34055847-5AEE1556-9C8D-46C6-9532-F702A736C638Q34069846-6A2A3819-5580-40D6-8425-13E7368E24FFQ34078521-855D90A5-B07D-43F2-A631-F83ADE6C2066Q34165236-DEC140C6-8523-4847-9A76-4EAB46763A93Q34280466-77E6B008-857E-41A1-A04F-992685749435Q34351993-F89A5590-4023-4728-9702-F65E1389C9F9Q34365035-97B5E554-2A1A-43DA-8831-040D261B4F8EQ34415921-1694980B-37DD-4D71-81E3-FD3C0DE03B6BQ35011932-3D816EAD-2C03-4661-B76C-90D89B3C4F5EQ35014689-A0DC6D22-B6D5-4E7F-8BAD-99622D4B9BE2Q35061450-BD4B40EF-2516-4074-B86C-8B9A0F23A4A4Q35547902-A59FF455-58BA-44CC-90D7-70594FD74677Q35683008-D8FA5152-4D75-4AC6-8A53-3667FF35FCA3Q35910232-4834AE1E-7EE7-43FF-A2E8-8881AA75E971Q35943647-9933BFE9-18BA-4A72-8978-7FF46C1C106BQ35976966-21691A99-FDA3-4FF7-9349-B0424D2D2D16Q35978823-41161FBB-D1FD-4FFF-82DE-F48DF8FC0520Q36082073-6F22125B-BB0D-4708-BD9C-90E9EE4CB45AQ36379335-810638C8-3D82-4008-A8FD-8260BA1DD115Q36458359-9C4189AE-F38A-4B2C-A17C-6D50A2B80988Q36525116-92B20456-D7B7-4A23-99FA-B9CD6DD1433CQ37123271-A72836A5-7AA6-4CB0-A18C-028F7C646035Q37175177-D095C68E-E6DA-4D7C-9DF5-DF1F6FEAA040Q37570103-50ADEAA4-2E50-4506-B43C-2BC4FC75810CQ37596642-596409BF-9AEB-4FFF-A406-67904A078A97Q37803237-B04648B9-17FE-47A7-9778-932F2F486E62Q37961181-64563406-A37B-44B8-BB17-D6FEF7662010Q38114781-73146794-97EE-4FDE-B4CF-69F2713AE535
P2860
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
The safety, plasma pharmacokin ...... usion, in HIV-infected adults.
@en
The safety, plasma pharmacokin ...... usion, in HIV-infected adults.
@nl
type
label
The safety, plasma pharmacokin ...... usion, in HIV-infected adults.
@en
The safety, plasma pharmacokin ...... usion, in HIV-infected adults.
@nl
prefLabel
The safety, plasma pharmacokin ...... usion, in HIV-infected adults.
@en
The safety, plasma pharmacokin ...... usion, in HIV-infected adults.
@nl
P2093
P50
P1476
The safety, plasma pharmacokin ...... fusion, in HIV-infected adults
@en
P2093
Alex Dusek
Calvin Cohen
Emily L Nelson
Jacob P Lalezari
Jeffrey C Goodgame
Joel E Gallant
Margrit Carlson
Michael S Saag
Paul Volberding
Prakash R Sista
P304
P356
10.1089/088922202760072294
P577
2002-07-01T00:00:00Z